Insulin Glargine 300&#160;U/mL: A Review in Diabetes Mellitus (Q38715053)

5 September 2017

Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus (English)

1 reference

5 September 2017

1 reference

2

Gillian M Keating

1 reference

5 September 2017

Hannah A Blair

1

1 reference

5 September 2017

28 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

76

1 reference

5 September 2017

3

1 reference

5 September 2017

363-374

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0541-z

5 September 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Standards of medical care in diabetes-2015 abridged for primary care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New Insulins and New Aspects in Insulin Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Insulin glargine: an updated review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0541-Z

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26821280

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26821280

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-016-0541-Z

1 reference

PubMed ID

26821280

Dimensions Publication ID

5 September 2017

0 references

1 reference

PubMed ID

26821280